ATM and neoplasm: This has offered a therapeutic vulnerability that has been extensively explored clinically in BRCA1/2 mutant patients but is now also being examined as a viable therapy in tumours with other specific genotypes, including those presenting with ATM, PALB2, RAD51C, and RAD51D mutations [117].